Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Retained Earnings (2021 - 2025)

Aligos Therapeutics' Retained Earnings history spans 5 years, with the latest figure at -$642.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 142494.9% year-over-year to -$642.2 million; the TTM value through Dec 2025 reached -$642.2 million, down 142494.9%, while the annual FY2025 figure was -$642.2 million, 142494.9% down from the prior year.
  • Retained Earnings reached -$642.2 million in Q4 2025 per ALGS's latest filing, down from -$622.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $497000.0 in Q2 2023 to a low of -$642.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$298.7 million, with a median of -$348.7 million recorded in 2022.
  • The largest YoY upside for Retained Earnings was 100.14% in 2023 against a maximum downside of 288716.35% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $452000.0 in 2021, then decreased by 11.28% to $401000.0 in 2022, then plummeted by 121495.76% to -$486.8 million in 2023, then skyrocketed by 100.09% to $451000.0 in 2024, then plummeted by 142494.9% to -$642.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Retained Earnings are -$642.2 million (Q4 2025), -$622.3 million (Q3 2025), and $420000.0 (Q2 2025).